Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma
- 2 January 2017
- journal article
- research article
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 56 (01) , 14-22
Abstract
Purpose: Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for 223Ra- dichloride therapy of bone metastases. The purpose of this study was to investigate whether 68Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for 223Ra-dichloride therapy. Methods: In 27 consecutive patients referred for 223Ra-dichloride therapy additional 68Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy. Results: In 4 patients (15 %) 68Ga- PSMA-PET revealed previously unknown visceral metastases (3 liver, 1 adrenal gland), which changed the therapeutic decision in 2 cases. PET revealed more extended tumour involvement in the bone compared to bone scintigraphy in 9 patients (33 %). In 3 of these, the mismatch was extensive enough to question suitability for 223Ra-dichloride therapy. Conclusions: Additional 68Ga-PSMA-PET as a gatekeeper between conventional staging and 223Ra-dichloride therapy can provide valuable additional information with regard to visceral metastases and tumour manifestations without adequate bone mineral turnover. It may lead to a change in therapeutic management in a significant number of patients and should therefore be considered in future clinical trials.Keywords
This publication has 23 references indexed in Scilit:
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Imaging of bone metastasis: An updateWorld Journal of Radiology, 2015
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialThe Lancet Oncology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastasesAnnals of Nuclear Medicine, 2013
- [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECHEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Technical note: identifying the prostate cancer ‘superscan’ by quantitative skeletal scintigraphyNuclear Medicine Communications, 2008
- The relation of radionuclide uptake by bone to the rate of calcium mineralization. II: Patient studies using 99Tcm-MDPBritish Journal of Radiology, 1989
- 99 Tc m -MDP and 99 Tc m -DPD in Pathologic Bone LesionsActa Radiologica, 1987